Document is current
Any future updates will be listed below
-
Authors
Liu, Sophie S. https://orcid.org/0000-0002-6616-1339
Shim, Surim
Kudo, Yoshimasa
Stabler, Cherie L.
O’Cearbhaill, Eoin D. https://orcid.org/0000-0002-4666-5863
Karp, Jeffrey M. https://orcid.org/0000-0002-4752-7374
Yang, Kisuk https://orcid.org/0000-0002-2724-5222
- License Information
-
More Information
Article History
Accepted: 5 August 2024
First Online: 24 September 2024
Competing interests
: J.M.K. has been a paid consultant and or equity holder for multiple companies; these include Alivio Therapeutics, Abercrombie and Fitch, Cobro Ventures, Altrix Bio, Stempeutics, Sanofi, Celltex, LifeVaultBio, Tissium, Takeda, Skintifique, Corner Therapeutics, Ligandal, Lumicell, Guidepoint Global, Biomodels, One Fun Company, Katharos Labs, Triton Systems, Edge Immune, W. L. Gore, Camden Partners, Stemgent, Gyro Gear, Mirakel Labs, Janssen Research & Development, Biogen, Pancryos, IP Asset Ventures, Enlight Biosciences, Mesoblast, SRU Biosystems, New Frontier Bio, Clear Nanosystems, Bullseye Therapeutics, Schick Manufacturing Inc, Biolacuna, Oakley, Element Biosciences, Frequency Therapeutics, Molecular Infusions, Quthero and Vyome. J.M.K. holds equity in several companies that have licensed intellectual property generated by him that may benefit financially if the intellectual property is further validated. The interests of J.M.K. were reviewed and are subject to a management plan overseen by his institutions in accordance with its conflict-of-interest policies. E.D.O’C. has been a paid consultant for Pancryos. S.S.L., Y.K., S.S., C.L.S. and K.Y. declare no competing interests.
